BUDAPEST, Hungary, June 21, 2023 /PRNewswire/ — Mediso has announced the Food and Drug Administration (FDA) clearance of multimodality imaging (PET/SPECT/MRI/CT) processing and reporting software ) InterView™ FUSION and InterView™ XP, tailored specifically for nuclear medicine and molecular imaging workflows.
Vendor-independent InterView™ software offers a complete solution for image viewing, post-processing and reporting specifically tailored for routine molecular imaging and nuclear medicine workflow. Workflows and specialized tools cover the most common nuclear medicine studies, including bone, cardiac, central nervous system, thyroid, parathyroid, renal, liver, GI, and pulmonary. Rapid, standardized reports are available for all nuclear medicine procedures. The software improves SPECT image quality with iterative reconstruction and achieves absolute quantification with the Tera-Tomo™ SPECT reconstruction engine, enabling fast and accurate custom dosimetry. It also features a variety of state-of-the-art modules to enhance clinical and preclinical research work, such as automatic lesion detection, automatic segmentation, and image denoising. InterView™ software integrates seamlessly with any hospital information system, whether running on a stand-alone workstation or on a physical or virtualized server.
“Receiving FDA clearance for our imaging software marks the next step in bringing our clinical products to market in the US,” said Istvan Bagamery, founder and CEO of Mediso. “InterView™ software together with the clinical AnyScan SPECT and SPECT/CT systems provide a complete solution for all routine and research applications in nuclear medicine and demonstrate our continued commitment to the molecular imaging market.”
Mediso has been working in the field of medical imaging for more than 30 years with a profile of development, manufacture, sale and maintenance of independent and multimodality imaging devices. The company offers complete solutions, from hardware design to assessment and quantification software for clinical patient care and preclinical research.
Mediso occupies a leading position in the clinical nuclear medicine market, with more than 1,500 systems in service worldwide. In addition to the market-leading AnyScan TRIO SPECT/CT, Mediso also offers an integrated triple-modality SPECT/PET/CT system that is unique to the market.
Products are sold directly or through a distribution network in more than 100 countries around the world.
Logo – https://mma.prnewswire.com/media/2077004…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/mediso-recibe-la-aprobacion-de-la-fda-para-el-software-de-procesamiento-de-imagenes-de-medicina-nuclear-interview-301855291.html
